{"id":3401,"date":"2025-11-18T17:43:23","date_gmt":"2025-11-18T08:43:23","guid":{"rendered":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/?page_id=3401"},"modified":"2026-01-11T14:43:02","modified_gmt":"2026-01-11T05:43:02","slug":"2021-2","status":"publish","type":"page","link":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/2021-2\/","title":{"rendered":"2021"},"content":{"rendered":"

2021 (\u8ad6\u6587)<\/h2>\n
    \n
  1. Ogawa Y, Kimura H, Fujimoto H, Kawashima H, Toyoda K, Mukai E, Yagi Y, Ono M, Inagaki N, Saji H.<\/span><\/span><\/span>
    \n<\/span><\/span><\/span>Development of Novel Radioiodinated Exendin-4 Derivatives Targeting GLP-1 Receptor for Detection of \u03b2-cell Mass<\/span><\/span><\/span><\/span>
    \n<\/span><\/span><\/span><\/span>Bioorg. Med. Chem.<\/em>\u00a052 116496 (2021)<\/span><\/span><\/li>\n
  2. Iikuni S, Kitano A, Watanabe H, Ono M.<\/span><\/span><\/span>
    \n<\/span><\/span><\/span>Feasibility of 99m<\/sup>Tc-hydroxamamide complex based on (iodophenyl)butyric acid as albumin-binding moiety for tumor imaging via in vivo labeling of albumin<\/span><\/span><\/span><\/span>
    \n<\/span><\/span><\/span><\/span>Bioorg. Med. Chem. Lett.<\/em>\u00a053 128417 (2021)<\/span><\/span><\/li>\n
  3. Shimizu Y, Ando M, Iikuni S, Watanabe H, Ono M.<\/span><\/span><\/span>
    \n<\/span><\/span><\/span>Development of a hydroxamamide-based bifunctional chelating agent to prepare technetium-99m-labeled bivalent ligand probes<\/span><\/span><\/span><\/span>
    \n<\/span><\/span><\/span><\/span>Sci. Rep.<\/em>\u00a011 18714 (2021)<\/span><\/span><\/li>\n
  4. Iikuni S, Tarumizu Y, Nakashima K, Higaki Y, Ichikawa H, Watanabe H, Ono M.<\/span><\/span><\/span>
    \n<\/span><\/span><\/span>Radiotheranostics using a novel 225<\/sup>Ac-labeled radioligand with improved pharmacokinetics targeting prostate-specific membrane antigen<\/span><\/span><\/span><\/span>
    \n<\/span><\/span><\/span><\/span>J. Med. Chem.<\/em>\u00a064(18) 13429-13438 (2021)<\/span><\/span><\/li>\n
  5. Fujimoto H, Fujita N, Hamamatsu K, Murakami T, Nakamoto Y, Saga T, Ishimori T, Shimizu Y, Watanabe H, Sano K, Harada N, Nakamura H, Toyoda K, Kimura H, Nakagawa S, Hirai M, Murakami A, Ono M, Togashi K, Saji H, Inagaki N.<\/span><\/span><\/span>
    \n<\/span><\/span><\/span>First-In-Human Evaluation of Positron Emission Tomography\/Computed Tomography with [18<\/sup>F]FB(ePEG12)12-Exendin-4: A Phase 1 Clinical Study Targeting GLP-1 Receptor Expression Cells in Pancreas<\/span><\/span><\/span><\/span>
    \n<\/span><\/span><\/span><\/span>Front. Endocrinol.<\/em>\u00a012, 717101 (2021)<\/span><\/span><\/li>\n
  6. Nakashima K, Iikuni S, Watanabe H, Ono M.<\/span><\/span><\/span>
    \n<\/span><\/span><\/span>Development of a novel radiotheranostic platform with a DOTA-based trifunctional chelating agent<\/span><\/span><\/span><\/span>
    \n<\/span><\/span><\/span><\/span>Chem. Commun.<\/em>\u00a057 6432-6435 (2021)<\/span><\/span><\/li>\n
  7. Watanabe H, Idoko Y, Iikuni S, Ide T, Shimizu Y, Nakamoto Y, Ono M.<\/span><\/span><\/span>
    \n<\/span><\/span><\/span>Synthesis and biological evaluation of novel 18<\/sup>F-labeled phenylbenzofuran-2-carboxamide derivative for detection of orexin 1 receptor in the brain<\/span><\/span><\/span><\/span>
    \n<\/span><\/span><\/span><\/span>Bioorg. Med. Chem. Lett.<\/em> 43 128098 (2021)<\/span><\/span><\/li>\n
  8. Watanabe H, Kishimoto T, Kaide S, Tarumizu Y, Tatsumi H, Iikuni S, Ono M.<\/span><\/span><\/span>
    \n<\/span><\/span><\/span>Characterization and Optimization of Radioiodinated Benzimidazopyrimidine and Pyridoimidazopyridine Derivatives for Development of Tau Imaging Probes<\/span><\/span><\/span><\/span>
    \n<\/span><\/span><\/span><\/span>ACS Med. Chem. Lett.<\/em> 12(5) 805-811 (2021)<\/span><\/span><\/li>\n
  9. Iikuni S, Okada Y, Shimizu Y, Watanabe H, Ono M.<\/span><\/span><\/span>
    \n<\/span><\/span><\/span>Modulation of pharmacokinetics of radioligand targeting carbonic anhydrase-IX utilizing albumin-binding moiety<\/span><\/span><\/span><\/span>
    \n<\/span><\/span><\/span><\/span>Mol. Pharm.<\/em>\u00a018(3) 966-975 (2021)<\/span><\/span><\/li>\n
  10. Shimizu Y, Nakai Y, Watanabe H, Iikuni S, Ono M, Saji H, Kuge Y, Saga T, Nakamoto Y.<\/span><\/span><\/span>
    \n<\/span><\/span><\/span>Increased [18<\/sup>F]FMISO accumulation under hypoxia by multi-drug resistant protein 1 inhibitors<\/span><\/span><\/span><\/span>
    \n<\/span><\/span><\/span><\/span>EJNMMI res.<\/em>\u00a011 9 (2021)<\/span><\/span><\/li>\n
  11. Watanabe H, Tarumizu Y, Kaide S, Shimizu Y, Iikuni S, Nakamoto Y, Ono M.<\/span><\/span><\/span>
    \n<\/span><\/span><\/span>Structure-Activity and Brain Kinetics Relationships of 18<\/sup>F Labeled Benzimidazopyridine Derivatives as Tau PET Tracers<\/span><\/span><\/span><\/span>
    \n<\/span><\/span><\/span><\/span>ACS Med. Chem. Lett.<\/em>\u00a012(2) 262-266 (2021)<\/span><\/span><\/li>\n
  12. Shimizu Y, Nakai Y, Iikuni S, Watanabe H, Nakamoto Y, Ono M.<\/span><\/span><\/span>
    \n<\/span><\/span><\/span>Synthesis and Evaluation of Gallium-68-labeled Nitroimidazole Based Imaging Probes for PET Diagnosis of Tumor Hypoxia<\/span><\/span><\/span><\/span>
    \n<\/span><\/span><\/span><\/span>Ann. Nucl. Med.<\/em>\u00a035(3) 360-369 (2021)<\/span><\/span><\/li>\n
  13. Nakashima K, Iikuni S, Okada Y, Watanabe H, Shimizu Y, Nakamoto Y, Ono M.<\/span><\/span><\/span>
    \n<\/span><\/span><\/span>Evaluation of 68<\/sup>Ga-labeled Imidazothiadiazole Sulfonamide Derivatives for PET Imaging of Carbonic Anhydrase-IX<\/span><\/span><\/span><\/span>
    \n<\/span><\/span><\/span><\/span>Nucl. Med. Biol.<\/em> 93, 46-53 (2021)<\/span><\/span><\/li>\n<\/ol>\n

    \u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\u623b\u308b<\/a><\/p>\n

    2021 (\u8457\u66f8\u7b49)<\/h2>\n
      \n
    1. \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span>
      \n<\/span><\/span><\/span><\/span>SPECT\u7528\u30bf\u30a6\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span>
      \n\u7d30\u80de<\/em>\u00a053(1) 41-43 (2021)<\/li>\n<\/ol>\n

      \u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\u623b\u308b<\/a><\/p>\n

      2021 (\u5b66\u4f1a\u767a\u8868)<\/h2>\n
        \n
      1. Shimpei Iikuni, Yusuke Higaki, Hiroaki Ichikawa, Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span>
        \nDevelopment of novel radiotheranostic ligand targeting prostate-specific membrane antigen with improved pharmacokinetics<\/span>
        \n<\/span><\/span><\/span><\/span>The 11th China-Japan-Korea Symposium on Radiopharmaceutical Sciences (Seoul (Online)) November\u00a011-12, 2021<\/span><\/span><\/span><\/li>\n
      2. Simpei Iikuni, <\/span>Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span>
        \nTumor-specific delivery of radioligands targeting carbonic anhydrase-IX utilizing albumin binder<\/span>
        \n<\/span><\/span><\/span><\/span>eSRS 2021 Virtual Meeting (Online) May 17-19, 2021<\/span><\/span><\/span><\/li>\n
      3. \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
        \n<\/span>\u8133\u30bf\u30f3\u30d1\u30af\u8cea\u51dd\u96c6\u4f53\u306e\u751f\u4f53\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u6280\u8853(\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0)<\/span><\/span><\/span><\/span><\/span><\/span>
        \n\u7b2c40\u56de\u65e5\u672c\u8a8d\u77e5\u75c7\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u6771\u4eac\uff09 2021\u5e7411\u670826\u65e5\u301c28\u65e5<\/span><\/span><\/span><\/li>\n
      4. \u8c9d\u51fa \u7fd4, \u6e21\u908a \u88d5\u4e4b, \u98ef\u570b \u614e\u5e73, \u5fd7\u6c34 \u967d\u4e00, \u9577\u8c37\u5ddd \u6210\u4eba, \u4f0a\u6771 \u606d\u5b50, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
        \n<\/span>\u30ab\u30eb\u30b3\u30f3\u985e\u7e01\u4f53\u3092\u57fa\u76e4\u3068\u3057\u305f\u03b1\u30b7\u30cc\u30af\u30ec\u30a4\u30f3\u6a19\u7684PET\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span>
        \n\u7b2c61\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u540d\u53e4\u5c4b\uff09 2021\u5e7411\u67084\u65e5\u301c\uff16\u65e5<\/span><\/span><\/span><\/li>\n
      5. \u5c3e\u4e0a \u907c\u592a\u90ce, \u6e21\u908a \u88d5\u4e4b, \u98ef\u570b \u614e\u5e73, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
        \n<\/span>\u30aa\u30fc\u30b8\u30a7\u6cbb\u7642\u3092\u76ee\u7684\u3068\u3057\u305f\u65b0\u898f\u653e\u5c04\u6027\u30e8\u30a6\u7d20BODIPY\u8a98\u5c0e\u4f53\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span>
        \n\u7b2c61\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u540d\u53e4\u5c4b\uff09 2021\u5e7411\u67084\u65e5\u301c\uff16\u65e5<\/span><\/span><\/span><\/li>\n
      6. \u98ef\u570b \u614e\u5e73, \u4e80\u4e95 \u77e5\u90ce, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
        \n<\/span>\u814e\u96c6\u7a4d\u4f4e\u6e1b\u3092\u76ee\u6307\u3057\u305f\u65b0\u898f111<\/sup>In\u6a19\u8b58GLP-1\u53d7\u5bb9\u4f53\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span>
        \n\u7b2c61\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u540d\u53e4\u5c4b\uff09 2021\u5e7411\u67084\u65e5\u301c\uff16\u65e5<\/span><\/span><\/span><\/li>\n
      7. \u4e2d\u5cf6 \u4e00\u78e8, \u98ef\u570b \u614e\u5e73, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
        \n<\/span>\u30af\u30ea\u30c3\u30af\u53cd\u5fdc\u3092\u5229\u7528\u3057\u305f\u65b0\u898f\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u7528\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span>
        \n\u7b2c61\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u540d\u53e4\u5c4b\uff09 2021\u5e7411\u67084\u65e5\u301c\uff16\u65e5<\/span><\/span><\/span><\/li>\n
      8. \u6e21\u908a \u88d5\u4e4b<\/span><\/span><\/span>
        \n<\/span>Development of PET probes targeting orexin receptors in the brain (\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0)<\/span><\/span><\/span><\/span><\/span><\/span>
        \n\u7b2c61\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u540d\u53e4\u5c4b\uff09 2021\u5e7411\u67084\u65e5\u301c\uff16\u65e5<\/span><\/span><\/span><\/li>\n
      9. \u9f4b\u85e4 \u6d69\u8f14, \u6e21\u908a \u88d5\u4e4b, \u98ef\u570b \u614e\u5e73, \u5c0f\u91ce \u6b63\u535a\u00a0<\/span><\/span>
        \n<\/span>\u591a\u4fa1\u52b9\u679c\u306b\u3088\u308b\u89aa\u548c\u6027\u5411\u4e0a\u3092\u4f01\u56f3\u3057\u305f\u65b0\u898f\u81b5\u5cf6\u30a2\u30df\u30ed\u30a4\u30c9\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a<\/span><\/span><\/span>
        \n\u7b2c71\u56de \u65e5\u672c\u85ac\u5b66\u4f1a\u95a2\u897f\u652f\u90e8\u7dcf\u4f1a\u30fb\u5927\u4f1a<\/span>\uff08\u5927\u962a(\u30aa\u30f3\u30e9\u30a4\u30f3))\u00a0\u00a0<\/span>2021\u5e7410\u67089\u65e5<\/span><\/span><\/li>\n
      10. \u98ef\u570b \u614e\u5e73, \u6a9c\u57a3 \u4f51\u8f14, \u5e02\u5ddd \u6d69\u7ae0, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a\u00a0<\/span><\/span>
        \n<\/span>\u524d\u7acb\u817a\u304c\u3093\u306e\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u306b\u8cc7\u3059\u308b\u65b0\u898fAc-225\u6a19\u8b58\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a<\/span><\/span><\/span>
        \n\u7b2c4\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5206\u79d1\u4f1a \u653e\u5c04\u6027\u85ac\u54c1\u79d1\u5b66\u7814\u7a76\u4f1a\/<\/span>\u7b2c<\/span>19<\/span>\u56de\u653e\u5c04\u6027\u533b\u85ac\u54c1\u30fb\u753b\u50cf\u8a3a\u65ad\u85ac\u7814\u7a76\u4f1a<\/span>\uff08\u4ed9\u53f0(\u30aa\u30f3\u30e9\u30a4\u30f3))\u00a0\u00a0<\/span>2021\u5e749\u670825\u65e5<\/span><\/span><\/li>\n
      11. \u4e2d\u5ddd \u822a\u5e73, \u6e21\u908a \u88d5\u4e4b, \u8c9d\u51fa \u7fd4, \u98ef\u570b \u614e\u5e73, \u5fd7\u6c34 \u967d\u4e00, \u5c0f\u91ce \u6b63\u535a<\/span><\/span>
        \n<\/span>\u03b1\u30b7\u30cc\u30af\u30ec\u30a4\u30f3\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a\u3092\u76ee\u7684\u3068\u3057\u305f\u65b0\u898f18<\/sup>F\u6a19\u8b58\u30b9\u30c1\u30ea\u30eb\u30ad\u30ce\u30ea\u30f3\/\u30ad\u30ce\u30ad\u30b5\u30ea\u30f3\u8a98\u5c0e\u4f53\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span><\/span><\/span>
        \n\u7b2c4\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5206\u79d1\u4f1a \u653e\u5c04\u6027\u85ac\u54c1\u79d1\u5b66\u7814\u7a76\u4f1a\/<\/span>\u7b2c20<\/span>\u56de\u653e\u5c04\u6027\u533b\u85ac\u54c1\u30fb\u753b\u50cf\u8a3a\u65ad\u85ac\u7814\u7a76\u4f1a<\/span>\uff08\u4ed9\u53f0(\u30aa\u30f3\u30e9\u30a4\u30f3))\u00a0\u00a0<\/span>2021\u5e749\u670825\u65e5<\/span><\/span><\/li>\n
      12. \u98ef\u570b \u614e\u5e73, \u5317\u91ce \u674f\u5948, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span>
        \n<\/span>\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u306e\u52b9\u679c\u4e88\u6e2c\u3092\u76ee\u7684\u3068\u3057\u305f\u30b0\u30e9\u30f3\u30b6\u30a4\u30e0B\u6a19\u7684\u653e\u5c04\u6027\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a<\/span><\/span><\/span>
        \n\u7b2c4\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5206\u79d1\u4f1a \u653e\u5c04\u6027\u85ac\u54c1\u79d1\u5b66\u7814\u7a76\u4f1a\/<\/span>\u7b2c20<\/span>\u56de\u653e\u5c04\u6027\u533b\u85ac\u54c1\u30fb\u753b\u50cf\u8a3a\u65ad\u85ac\u7814\u7a76\u4f1a<\/span>\uff08\u4ed9\u53f0(\u30aa\u30f3\u30e9\u30a4\u30f3))\u00a0\u00a0<\/span>2021\u5e749\u670825\u65e5<\/span><\/span><\/li>\n
      13. \u6570\u591a \u4f38\u7d00, \u98ef\u570b \u614e\u5e73, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span>
        \n<\/span><\/span>\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u7642\u6cd5\u306e\u6cbb\u7642\u52b9\u679c\u4e88\u6e2c\u3092\u76ee\u7684\u3068\u3057\u305f\u65b0\u898f\u30b0\u30e9\u30f3\u30b6\u30a4\u30e0B\u6a19\u7684111<\/sup>In\u6a19\u8b58\u5316\u5408\u7269\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span><\/span><\/span><\/span><\/span>
        \n\u7b2c18\u56de\u6b21\u4e16\u4ee3\u3092\u62c5\u3046\u82e5\u624b\u306e\u305f\u3081\u306e\u30d5\u30a3\u30b8\u30ab\u30eb\u30fb\u30d5\u30a1\u30fc\u30de\u30d5\u30a9\u30fc\u30e9\u30e0 (\u4ed9\u53f0(\u30aa\u30f3\u30e9\u30a4\u30f3))\u00a02021\u5e749\u670814\u65e5, 15\u65e5<\/span><\/span><\/li>\n
      14. \u8d64\u5742 \u8cb4\u6d69, \u6e21\u908a \u88d5\u4e4b, \u8c9d\u51fa \u7fd4, \u98ef\u570b \u614e\u5e73, \u5c0f\u91ce \u6b63\u535a<\/span>
        \n<\/span><\/span>\u03b1\u30b7\u30cc\u30af\u30ec\u30a4\u30f3\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a\u3092\u76ee\u7684\u3068\u3057\u305f\u653e\u5c04\u6027\u30e8\u30a6\u7d20\u6a19\u8b58\u30aa\u30fc\u30ed\u30f3\u8a98\u5c0e\u4f53\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span><\/span><\/span><\/span><\/span>
        \n\u7b2c18\u56de\u6b21\u4e16\u4ee3\u3092\u62c5\u3046\u82e5\u624b\u306e\u305f\u3081\u306e\u30d5\u30a3\u30b8\u30ab\u30eb\u30fb\u30d5\u30a1\u30fc\u30de\u30d5\u30a9\u30fc\u30e9\u30e0 (\u4ed9\u53f0(\u30aa\u30f3\u30e9\u30a4\u30f3))\u00a02021\u5e749\u670814\u65e5, 15\u65e5<\/span><\/span><\/li>\n
      15. \u8c9d\u51fa \u7fd4, \u6e21\u908a \u88d5\u4e4b, \u98ef\u570b \u614e\u5e73, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span>
        \n\u795e\u7d4c\u5909\u6027\u75be\u60a3\u306b\u304a\u3051\u308b\u8133\u30bf\u30f3\u30d1\u30af\u8cea\u51dd\u96c6\u4f53\u3092\u6a19\u7684\u3068\u3057\u305f\u6838\u533b\u5b66\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u6cd5\u306e\u958b\u767a (\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0)<\/span><\/span><\/span>
        \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c141\u5e74\u4f1a (\u5e83\u5cf6(\u30aa\u30f3\u30e9\u30a4\u30f3)) 2021\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/li>\n
      16. \u4e2d\u5cf6 \u4e00\u78e8, \u98ef\u570b \u614e\u5e73, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
        \n\u30af\u30ea\u30c3\u30af\u30b1\u30df\u30b9\u30c8\u30ea\u30fc\u3092\u5229\u7528\u3057\u305f\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u7528\u4e09\u5b98\u80fd\u6027\u30ad\u30ec\u30fc\u30c8\u8a66\u85ac\u306e\u5408\u6210\u3068\u57fa\u790e\u7684\u8a55\u4fa1<\/span><\/span><\/span>
        \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c141\u5e74\u4f1a (\u5e83\u5cf6(\u30aa\u30f3\u30e9\u30a4\u30f3)) 2021\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/li>\n
      17. \u98ef\u570b \u614e\u5e73, \u6e21\u908a \u88d5\u4e4b, \u6a9c\u57a3 \u4f51\u8f14, \u5e02\u5ddd \u6d69\u7ae0, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
        \n\u304c\u3093\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u3092\u76ee\u7684\u3068\u3057\u305f\u65b0\u898f225<\/sup>Ac\u6a19\u8b58PSMA\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a<\/span><\/span><\/span>
        \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c141\u5e74\u4f1a (\u5e83\u5cf6(\u30aa\u30f3\u30e9\u30a4\u30f3)) 2021\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/li>\n
      18. \u5782\u6c34 \u52c7\u592a, \u98ef\u570b \u614e\u5e73, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
        \n\u30d4\u30b3\u30ea\u30f3\u9178\u7cfb\u91d1\u5c5e\u914d\u4f4d\u5b50\u3092\u57fa\u76e4\u3068\u3057\u305f\u65b0\u898f\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u85ac\u5264\u306e\u958b\u767a<\/span><\/span><\/span>
        \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c141\u5e74\u4f1a (\u5e83\u5cf6(\u30aa\u30f3\u30e9\u30a4\u30f3)) 2021\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/li>\n
      19. \u524d\u5ddd \u9234\u9999,\u00a0<\/span>\u6e21\u908a \u88d5\u4e4b,\u00a0<\/span>\u98ef\u570b \u614e\u5e73, \u62b1 \u5c06\u53f2<\/span>,\u00a0<\/span>\u677e\u5c3e \u51ea\u7d17,\u00a0<\/span>\u767d\u5ddd \u4e45\u5fd7,\u00a0<\/span>\u91d1\u5b50 \u5468\u53f8,\u00a0<\/span>\u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
        \n\u591a\u767a\u6027\u786c\u5316\u75c7\u306e\u8a3a\u65ad\u3092\u76ee\u7684\u3068\u3057\u305f\u30df\u30a8\u30ea\u30f3\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a\uff1a\u653e\u5c04\u6027\u30e8\u30a6\u7d20\u6a19\u8b58\u30b8\u30a2\u30ea\u30fc\u30eb\u30aa\u30ad\u30b5\u30b8\u30a2\u30be\u30fc\u30eb\u8a98\u5c0e\u4f53\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span><\/span><\/span>
        \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c141\u5e74\u4f1a (\u5e83\u5cf6(\u30aa\u30f3\u30e9\u30a4\u30f3)) 2021\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/li>\n
      20. \u6e21\u908a \u88d5\u4e4b, \u5cb8\u672c \u5cfb\u660e, \u8c9d\u51fa \u7fd4, \u5782\u6c34 \u52c7\u592a, \u98ef\u570b \u614e\u5e73, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
        \n\u542b\u7a92\u7d20\u7e2e\u54083\u74b0\u7cfb\u69cb\u9020\u3092\u57fa\u76e4\u3068\u3057\u305f\u65b0\u898fSPECT\u7528\u30bf\u30a6\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a<\/span><\/span><\/span>
        \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c141\u5e74\u4f1a (\u5e83\u5cf6(\u30aa\u30f3\u30e9\u30a4\u30f3)) 2021\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/li>\n
      21. \u4e2d\u5ddd \u822a\u5e73, \u6e21\u908a \u88d5\u4e4b, \u8c9d\u51fa \u7fd4, \u98ef\u570b \u614e\u5e73, \u9577\u8c37\u5ddd \u6210\u4eba, \u4f0a\u6771 \u606d\u5b50,\u00a0<\/span>\u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
        \n\u03b1\u30b7\u30cc\u30af\u30ec\u30a4\u30f3\u306e\u751f\u4f53\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u3092\u76ee\u7684\u3068\u3057\u305f\u653e\u5c04\u6027\u30e8\u30a6\u7d20\u6a19\u8b58\u30b9\u30c1\u30ea\u30eb\u30ad\u30ce\u30ad\u30b5\u30ea\u30f3\u8a98\u5c0e\u4f53\u306e\u5408\u6210\u304a\u3088\u3073\u8a55\u4fa1<\/span><\/span><\/span>
        \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c141\u5e74\u4f1a (\u5e83\u5cf6(\u30aa\u30f3\u30e9\u30a4\u30f3)) 2021\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/li>\n
      22. \u5317\u91ce \u674f\u5948, \u98ef\u570b \u614e\u5e73, \u6e21\u908a \u88d5\u4e4b, \u7389\u7530 \u592a\u90ce, \u5c0f\u91ce \u6b63<\/span><\/span><\/span>\u535a<\/span><\/span><\/span>
        \n<\/span>\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u306e\u52b9\u679c\u4e88\u6e2c\u306b\u8cc7\u3059\u308b\u30b0\u30e9\u30f3\u30b6\u30a4\u30e0B\u6a19\u7684\u6838\u533b\u5b66\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a\uff1a\u65b0\u898f\u653e\u5c04\u6027\u30e8\u30a6\u7d20\u6a19\u8b58\u30c6\u30c8\u30e9\u30da\u30d7\u30c1\u30c9\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span><\/span><\/span>
        \n\u65e5\u672c<\/span>\u85ac\u5b66\u4f1a \u7b2c141\u5e74\u4f1a (\u5e83\u5cf6(\u30aa\u30f3\u30e9\u30a4\u30f3)) 2021\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/li>\n<\/ol>\n

        \u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\u623b\u308b<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

        2021 (\u8ad6\u6587) Ogawa Y, Kimura H, Fujimoto H, Kawashima H, Toyoda K, Mukai E, Yagi Y, Ono M, Inagaki N, Saji H. Dev […]<\/p>\n","protected":false},"author":14,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_crdt_document":"","footnotes":""},"class_list":["post-3401","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/pages\/3401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/comments?post=3401"}],"version-history":[{"count":3,"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/pages\/3401\/revisions"}],"predecessor-version":[{"id":3423,"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/pages\/3401\/revisions\/3423"}],"wp:attachment":[{"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/media?parent=3401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}